ProShares UltraShort NASDAQ Biotechnology
10 hedge funds and large institutions have $6.05M invested in ProShares UltraShort NASDAQ Biotechnology in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.95% more ownership
Funds ownership: 17.43% → 18.38% (+0.95%)
0% more capital invested
Capital invested by funds: $6.05M → $6.05M (+$1K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 11 → 10 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$1.56M |
| 2 |
HF
HRT Financial
New York
|
+$236K |
| 3 |
Jane Street
New York
|
+$168K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$165K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$43.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.04M |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$316K |
| 3 |
VF
Virtu Financial
New York
|
-$270K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$68K |
| 5 |
Citigroup
New York
|
-$2.16K |
BIS Hedge Fund Activity: Q2 2018 in Review
10 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2018, worth a combined $6.05M — up 0.02% from $6.05M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIS and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Healthcare Value Capital, adding an estimated $1.56M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.04M sold.
- 10 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2018, down from 11 in Q1 2018.
- Funds reported $6.05M of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2018, up 0.02% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2018 and 2 closed out, a net change of -1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2018 was Healthcare Value Capital, an estimated $1.56M added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2018 was Susquehanna International Group, an estimated $1.04M sold.
Based on aggregated 13F filings for Q2 2018.